Akademik Veri Yönetim Sistemi
Turk Onkoloji Dergisi, cilt.31, sa.1, ss.15-17, 2015 (Scopus)
OBJECTIVE: The aim of the present study was to investigate nephrotoxicity development ratios and clinical results of nephrotoxicity in patients diagnosed with lung cancer who received cisplatin in chemotherapy protocol. METHODS: A total of 170 lung cancer patients were enrolled in the present prospective study. Renal functions were recorded for each patient before and after chemotherapy. Nephrotoxicity was defined as doubling in plasma creatinine concentration. Modification in treatment due to nephrotoxicity (reduction in cisplatin dosage, cisplatin interruption, or discontinuation of chemotherapy) was recorded during chemotherapy courses. RESULTS: Decreasement of creatinine clearance levels was observed following each course of chemotherapy, but was especially noteworthy following the 1st and 5th courses (p=0.002; p=0.007, respectively). Nephrotoxicity was observed in 19 of the 170 patients (11%), in 10 of whom (53%) cisplatin dosage was reduced, and in 8 of whom (42%), cisplatin treatment was interrupted. Chemotherapy was discontinued in 1 patient (5%). CONCLUSION: Particularly following the fourth course, chemotherapy must be carefully administered due to risk of nephrotoxicity.